-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, J&J's Subcutaneous RYBREVANT FASPRO Plus LAZCLUZE Shows Lower Rash, Administration-Related Reaction, Venous Thromboembolism Rates Than Intravenous MARIPOSA Regimen

Benzinga·09/15/2026 07:30:31
Listen to the news
  • Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxis
  • Fewer than 1% of patients discontinued treatment due to treatment-related events at one year
  • New findings from Johnson & Johnson build on the MARIPOSA survival benefit and strengthen evidence for RYBREVANT FASPRO plus LAZCLUZE as first-line treatment